{"id":1033,"date":"2026-11-19T00:02:21","date_gmt":"2026-11-18T23:02:21","guid":{"rendered":"https:\/\/event.eortc.org\/ena2026\/?p=1033"},"modified":"2026-11-19T09:53:26","modified_gmt":"2026-11-19T08:53:26","slug":"antibody-drug-conjugate-designed-to-target-tumour-scaffolding-produces-positive-results","status":"publish","type":"post","link":"https:\/\/event.eortc.org\/ena2026\/2026\/11\/19\/antibody-drug-conjugate-designed-to-target-tumour-scaffolding-produces-positive-results\/","title":{"rendered":"Antibody-drug conjugate designed to target tumour \u2018scaffolding\u2019 produces positive results"},"content":{"rendered":"<p><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container has-pattern-background has-mask-background nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:63px;--awb-border-radius-top-right:63px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-overflow:hidden;--awb-padding-bottom:0px;--awb-margin-top:-63px;--awb-margin-bottom:0px;--awb-margin-top-small:-53px;--awb-background-color:var(--awb-color6);--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-end fusion-flex-content-wrap\" style=\"max-width:1248px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_1 1_1 fusion-flex-column\" style=\"--awb-bg-color:var(--awb-color6);--awb-bg-color-hover:var(--awb-color6);--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:1.92%;--awb-margin-bottom-large:8%;--awb-spacing-left-large:1.92%;--awb-width-medium:100%;--awb-order-medium:0;--awb-spacing-right-medium:1.92%;--awb-spacing-left-medium:1.92%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\" data-scroll-devices=\"small-visibility,medium-visibility,large-visibility\"><div class=\"fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column\"><\/div><\/div><\/div><\/div><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-2 fusion-flex-container has-pattern-background has-mask-background nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-padding-top:0px;--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:1248px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-1 fusion_builder_column_3_4 3_4 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-width-large:75%;--awb-margin-top-large:0px;--awb-spacing-right-large:2.56%;--awb-margin-bottom-large:20px;--awb-spacing-left-large:2.56%;--awb-width-medium:75%;--awb-order-medium:0;--awb-spacing-right-medium:2.56%;--awb-spacing-left-medium:2.56%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\"><div class=\"fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-text fusion-text-1\"><h3>Antibody-drug conjugate designed to target tumour \u2018scaffolding\u2019 produces positive results in phase I head and neck cancer trial<\/h3>\n<p><strong>19 November, Barcelona, Spain:<\/strong> An antibody-drug conjugate (ADC), called micvotabart pelidotin, or MICVO, has produced positive results in an early trial with head and neck cancer patients.<\/p>\n<p>The results, to be presented on Thursday at the 38th EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, are from a phase I trial in patients with recurrent or metastatic head and neck squamous cell carcinoma, whose tumours had continued to grow despite treatment with existing cancer drugs.<\/p>\n<p>MICVO has been designed to target the extracellular matrix, the supportive scaffolding present throughout a tumour, and then to release a powerful drug to kill nearby cancer cells and stimulate an immune response against the tumour.<\/p>\n<p>The results will be presented by Faye Johnson, professor of Thoracic\/ Head &amp; Neck Medical Oncology at The University of Texas MD Anderson Cancer Center, Houston, USA. She said: \u201cPatients with recurrent or metastatic head and neck squamous cell carcinoma do not have effective treatment options once their cancers stop responding to standard therapies, such as chemotherapy and immunotherapy. Currently available treatments produce tumour responses in fewer than 15% of cases. Even when responses occur, they are often short-lived, with disease progression typically occurring in less than two months and overall survival averaging less than six months.<\/p>\n<p>\u201cThe need for new treatments is substantial and continues to grow. In the United States, more than 30,000 patients begin first-line treatment for this type of cancer each year. Approximately 70% will see their disease progress and require second-line treatment, creating a population of roughly 21,000 patients annually who have very limited therapeutic options.\u201d<\/p>\n<p>The research included 36 patients with recurrent or metastatic head and neck squamous cell carcinoma treated at one of 29 cancer centres enrolling patients across the USA and Europe. The majority of patients had already had two or more cancer treatments.<\/p>\n<p>All the patients were treated with MICVO at 5.4 milligrams per kilogram of total body weight, every three weeks, up to a dose cap of 80 kilograms for males and 70 kilograms for females. Researchers were able to assess the antitumour effects of the drug in 33 of these patients.<\/p>\n<p>Researchers found that MICVO had a confirmed overall response rate (where the cancer shrinks by at least 30%) of 39%, including one patient with a complete response, and an average (median) progression-free survival (meaning the cancer does not grow or spread) of 6.7 months. The overall survival probability at one year was 81%. Researchers found similar responses in patients with different cancer subtypes including HPV-positive and HPV-unrelated cancers and in those previously treated with taxanes and\/or EGFR inhibitors.<\/p>\n<p>Professor Johnson said: \u201cMost of the responses were rapid and deep, occurring by the first assessment scans and resulting in a greater than 50% reduction in tumour size.<\/p>\n<p>\u201cSafety of the drug was manageable and consistent with prolonged exposure to auristatin, MICVO\u2019s anti-cancer drug. In the context of the benefit observed for patients, the overall benefit to risk profile provides meaningful promise for patients that lack effective treatment options.\u201d<\/p>\n<p>Serious (grade 3 or higher) treatment-related side effects experienced by two or more patients included neuropathy (nerve damage), raised liver enzymes, rash and low levels of white blood cells.<\/p>\n<p>MICVO targets a protein called extradomain-B of fibronectin (EDB+FN), which is often found at high levels in the extracellular matrix of tumours, including head and neck cancer, but is largely absent from other parts of the body. After binding to EDB+FN, MICVO releases a potent chemotherapy drug called auristatin.<\/p>\n<p>The makers of MICVO, Pyxis Oncology, plan to begin a global phase III trial in mid-2027 for patients with recurrent or metastatic head and neck squamous cell carcinoma who have already had at least one previous treatment. Researchers will continue to evaluate patients already treated with MICVO within clinical trials, both as a single treatment and in combination with other cancer drugs.<\/p>\n<p>Professor Elena Garralda, chair of the EORTC-NCI-AACR Symposium (ENA) and co-director of the Vall d\u2019Hebron Institute of Oncology\u2019s clinical research programme, was not involved with the study. She commented: \u201cHead and neck squamous cell carcinoma is a type of cancer that begins in the cells lining the mouth, throat and larynx. It is a common form of cancer, and it has become more common over recent decades. Although we have treatments for this type of cancer, we need more options for patients when our existing treatments fail. These early results show positive signs of clinical efficacy for MICVO with manageable side effects for the patients taking part.\u201d<\/p>\n<p>Abstract no: 3LBA, \u201c<a href=\"https:\/\/cm.eortc.org\/cmPortal\/Searchable\/ena2026\/config\/Normal#!sessiondetails\/0000115140_0\" target=\"_blank\" rel=\"noopener\">Phase 1 study of micvotabart pelidotin (MICVO) monotherapy in previously treated recurrent\/metastatic (R\/M) head and neck squamous cell carcinoma (HNSCC)<\/a>\u201d, by Faye Johnson, presented in the Proffered Papers: Clinical Trials session, 10:00 &#8211; 11:30 hrs CET, Thursday 19 November<\/p>\n<p><sup>[1] EORTC [European Organisation for Research and Treatment of Cancer], NCI [National Cancer Institute], AACR [American Association for Cancer Research]. The Symposium takes place in Barcelona from 18-20 November 2026.<\/sup><\/p>\n<p>Funding: Pyxis Oncology<\/p>\n<\/div><\/div><\/div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-2 fusion_builder_column_1_4 1_4 fusion-flex-column invisible\" style=\"--awb-bg-size:cover;--awb-width-large:25%;--awb-margin-top-large:18px;--awb-spacing-right-large:7.68%;--awb-margin-bottom-large:20px;--awb-spacing-left-large:7.68%;--awb-width-medium:25%;--awb-order-medium:0;--awb-spacing-right-medium:7.68%;--awb-spacing-left-medium:7.68%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\" data-scroll-devices=\"small-visibility,medium-visibility,large-visibility\"><div class=\"fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-title title fusion-title-1 fusion-sep-none fusion-title-text fusion-title-size-four invisible\" style=\"--awb-text-color:var(--awb-color1);--awb-margin-top-small:10px;--awb-margin-right-small:0px;--awb-margin-bottom-small:10px;--awb-margin-left-small:0px;\"><h4 class=\"fusion-title-heading title-heading-left\" style=\"margin:0;\">Recent posts<\/h4><\/div><div class=\"fusion-recent-posts fusion-recent-posts-1 avada-container layout-default layout-columns-1 invisible\"><section class=\"fusion-columns columns fusion-columns-1 columns-1\"><article class=\"post fusion-column column col col-lg-12 col-md-12 col-sm-12\"><div class=\"recent-posts-content\"><span class=\"vcard\" style=\"display: none;\"><span class=\"fn\"><a href=\"https:\/\/event.eortc.org\/ena2026\/author\/glyn\/\" rel=\"author\">glyn<\/a><\/span><\/span><span class=\"updated\" style=\"display:none;\">2026-11-19T09:49:07+01:00<\/span><h4 class=\"entry-title\"><a href=\"https:\/\/event.eortc.org\/ena2026\/2026\/11\/19\/antibody-drug-conjugate-shows-promising-early-results-in-phase-i-trial-in-sarcoma-patients\/\">Antibody-drug conjugate shows promising early results in phase I trial in sarcoma patients<\/a><\/h4><p>   Antibody-drug conjugate shows promising early results in phase I trial in sarcoma patients 19 November Barcelona, Spain: An antibody-drug conjugate, a type of drug that targets and enters cancer cells like a [...]<\/p><\/div><\/article><article class=\"post fusion-column column col col-lg-12 col-md-12 col-sm-12\"><div class=\"recent-posts-content\"><span class=\"vcard\" style=\"display: none;\"><span class=\"fn\"><a href=\"https:\/\/event.eortc.org\/ena2026\/author\/glyn\/\" rel=\"author\">glyn<\/a><\/span><\/span><span class=\"updated\" style=\"display:none;\">2026-11-19T09:32:23+01:00<\/span><h4 class=\"entry-title\"><a href=\"https:\/\/event.eortc.org\/ena2026\/2026\/11\/19\/new-drug-iacs-6274-shows-promise-in-phase-i-clinical-trial-treating-patients-with-advanced-ovarian-cancer\/\">New drug IACS-6274 shows promise in phase I clinical trial treating patients with advanced ovarian cancer<\/a><\/h4><p>    New drug IACS-6274 shows promise in phase I clinical trial treating patients with advanced ovarian cancer 19 November, Barcelona, Spain: Patients with advanced, hard-to-treat ovarian cancer have responded well to treatment [...]<\/p><\/div><\/article><article class=\"post fusion-column column col col-lg-12 col-md-12 col-sm-12\"><div class=\"recent-posts-content\"><span class=\"vcard\" style=\"display: none;\"><span class=\"fn\"><a href=\"https:\/\/event.eortc.org\/ena2026\/author\/glyn\/\" rel=\"author\">glyn<\/a><\/span><\/span><span class=\"updated\" style=\"display:none;\">2026-11-19T09:53:26+01:00<\/span><h4 class=\"entry-title\"><a href=\"https:\/\/event.eortc.org\/ena2026\/2026\/11\/19\/antibody-drug-conjugate-designed-to-target-tumour-scaffolding-produces-positive-results\/\">Antibody-drug conjugate designed to target tumour \u2018scaffolding\u2019 produces positive results<\/a><\/h4><p>    Antibody-drug conjugate designed to target tumour \u2018scaffolding\u2019 produces positive results in phase I head and neck cancer trial 19 November, Barcelona, Spain: An antibody-drug conjugate (ADC), called micvotabart pelidotin, or MICVO, [...]<\/p><\/div><\/article><\/section><\/div><div class=\"fusion-sharing-box fusion-sharing-box-1 invisible has-taglines layout-stacked layout-medium-stacked layout-small-stacked\" style=\"background-color:var(--awb-color5);border-color:#cccccc;--awb-separator-border-color:#cccccc;--awb-separator-border-sizes:0px;--awb-layout:column;--awb-alignment-small:space-between;--awb-stacked-align-small:center;\" data-title=\"Antibody-drug conjugate designed to target tumour \u2018scaffolding\u2019 produces positive results\" data-description=\"Antibody-drug conjugate designed to target tumour \u2018scaffolding\u2019 produces positive results in phase I head and neck cancer trial\r\n19 November, Barcelona, Spain: An antibody-drug conjugate (ADC), called micvotabart pelidotin, or MICVO, has produced positive results in an early trial with head and neck cancer patients.\r\n\r\nThe results, to be presented on Thursday at the\" data-link=\"https:\/\/event.eortc.org\/ena2026\/2026\/11\/19\/antibody-drug-conjugate-designed-to-target-tumour-scaffolding-produces-positive-results\/\"><h4 class=\"tagline\" style=\"color:var(--awb-color8);\">Share This Story<\/h4><div class=\"fusion-social-networks sharingbox-shortcode-icon-wrapper sharingbox-shortcode-icon-wrapper-1\"><span><a href=\"https:\/\/www.facebook.com\/sharer.php?u=https%3A%2F%2Fevent.eortc.org%2Fena2026%2F2026%2F11%2F19%2Fantibody-drug-conjugate-designed-to-target-tumour-scaffolding-produces-positive-results%2F\" target=\"_blank\" rel=\"noreferrer\" title=\"Facebook\" aria-label=\"Facebook\" data-placement=\"top\" data-toggle=\"tooltip\" data-title=\"Facebook\" data-><i class=\"fusion-social-network-icon fusion-tooltip fusion-facebook awb-icon-facebook\" style=\"color:var(--awb-color8);\" aria-hidden=\"true\"><\/i><\/a><\/span><span><a href=\"https:\/\/x.com\/intent\/post?text=Antibody-drug%20conjugate%20designed%20to%20target%20tumour%20%E2%80%98scaffolding%E2%80%99%20produces%20positive%20results&amp;url=https%3A%2F%2Fevent.eortc.org%2Fena2026%2F2026%2F11%2F19%2Fantibody-drug-conjugate-designed-to-target-tumour-scaffolding-produces-positive-results%2F\" target=\"_blank\" rel=\"noopener noreferrer\" title=\"X\" aria-label=\"X\" data-placement=\"top\" data-toggle=\"tooltip\" data-title=\"X\" data-><i class=\"fusion-social-network-icon fusion-tooltip fusion-twitter awb-icon-twitter\" style=\"color:var(--awb-color8);\" aria-hidden=\"true\"><\/i><\/a><\/span><span><a href=\"https:\/\/www.linkedin.com\/sharing\/share-offsite\/?url=https%3A%2F%2Fevent.eortc.org%2Fena2026%2F2026%2F11%2F19%2Fantibody-drug-conjugate-designed-to-target-tumour-scaffolding-produces-positive-results%2F\" target=\"_blank\" rel=\"noopener noreferrer\" title=\"LinkedIn\" aria-label=\"LinkedIn\" data-placement=\"top\" data-toggle=\"tooltip\" data-title=\"LinkedIn\" data-><i class=\"fusion-social-network-icon fusion-tooltip fusion-linkedin awb-icon-linkedin\" style=\"color:var(--awb-color8);\" aria-hidden=\"true\"><\/i><\/a><\/span><\/div><\/div><\/div><\/div><\/div><\/div><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":5,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1033","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/event.eortc.org\/ena2026\/wp-json\/wp\/v2\/posts\/1033","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/event.eortc.org\/ena2026\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/event.eortc.org\/ena2026\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/event.eortc.org\/ena2026\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/event.eortc.org\/ena2026\/wp-json\/wp\/v2\/comments?post=1033"}],"version-history":[{"count":5,"href":"https:\/\/event.eortc.org\/ena2026\/wp-json\/wp\/v2\/posts\/1033\/revisions"}],"predecessor-version":[{"id":1089,"href":"https:\/\/event.eortc.org\/ena2026\/wp-json\/wp\/v2\/posts\/1033\/revisions\/1089"}],"wp:attachment":[{"href":"https:\/\/event.eortc.org\/ena2026\/wp-json\/wp\/v2\/media?parent=1033"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/event.eortc.org\/ena2026\/wp-json\/wp\/v2\/categories?post=1033"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/event.eortc.org\/ena2026\/wp-json\/wp\/v2\/tags?post=1033"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}